Chen Bin, Wang Jizhe, Li Wei, Ji Wenyue
Department of Otolaryngology, 201 Hospital of PLA, Liaoyang 111000, China.
Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2006 Jul;20(14):649-51.
To study the expressions of androgen receptor (AR) and estrogen receptor (ER) in the pathogenesis of laryngeal carcinoma.
The method of in situ hybridization was employed to detect the expressions of AR and ER in 63 specimens of laryngeal carcinoma, 20 specimens of normal tissue beside carcinoma and 20 specimens of laryngeal benign lesion.
The expressions of AR and ER in specimens of normal tissue and laryngeal benign lesion were negative. The expressions of AR in laryngeal carcinomas was 68.3%, the expressions of ER was 69.8%, which was not correlated with sex and clinical classification (P > 0.05). With the differentiation of pathologic-classify and clinical stage, the expressions of AR in carcinoma of larynx were significantly increased, but ER was opposite (P < 0.05). The expression of AR was observed more frequently in patients with lymph node metastasis, but the expression of ER was degraded (P < 0.05). Compared with carcinoma of larynx, the expressions of AR and ER in specimens of normal tissue laryngeal benign lesion were significantly different (P < 0.01).
The expressions of sex hormone acceptor are concerned with the incidence of carcinoma of larynx. The expressions of AR and ER are closely related to pathologic-classify, clinical stage and lymph node metastasis. AR promoted the growth of laryngeal carcinoma, but ER restrained it. AR and ER could be marked to understand malignant degree and prognosis, but they were not correlated with sex and clinical classification. The difference in expression of AR and ER does not explain the difference of sex and incidence of laryngeal carcinoma difference in expression of AR and ER, it shows that the significant difference of sex in the incidence of carcinoma of larynx may be concerned with other factors.
研究雄激素受体（AR）和雌激素受体（ER）在喉癌发病机制中的表达情况。
采用原位杂交方法检测63例喉癌标本、20例癌旁正常组织标本和20例喉良性病变标本中AR和ER的表达。
正常组织和喉良性病变标本中AR和ER的表达均为阴性。喉癌中AR的表达率为68.3%，ER的表达率为69.8%，其与性别及临床分型无关（P>0.05）。随着病理分级和临床分期的增高，喉癌中AR的表达显著增加，而ER则相反（P<0.05）。有淋巴结转移患者中AR的表达更为常见，而ER的表达则降低（P<0.05）。与喉癌相比，正常组织和喉良性病变标本中AR和ER的表达有显著差异（P<0.01）。
性激素受体的表达与喉癌的发生有关。AR和ER的表达与病理分级、临床分期及淋巴结转移密切相关。AR促进喉癌生长，而ER则抑制其生长。AR和ER可作为判断恶性程度及预后的指标，但与性别及临床分型无关。AR和ER表达的差异并不能解释喉癌发病率的性别差异，提示喉癌发病率的性别显著差异可能与其他因素有关。
